FDA Issues Human Factors Guidance for Device Makers
Published Date: 5/29/2026
Notice
Summary
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
New Human Factors Submission Framework
On May 29, 2026, FDA issued final guidance that gives a risk-based framework describing the human factors information medical device manufacturers should include in marketing submissions to the Center for Devices and Radiological Health (CDRH). The guidance is intended to help make the FDA review process more efficient by clarifying what human factors content belongs in a submission.
60-Day Operationalization and Grace Period
FDA says the Agency and industry may need a minimum of 60 days to operationalize the policies in the guidance. For regulatory submissions currently pending after publication and for submissions received before August 1, 2026, FDA generally does not expect manufacturers will be ready to include the newly recommended information, though FDA will review any such information if it is submitted.
No New Paperwork Burden Declared
The guidance states it contains no new collection of information under the Paperwork Reduction Act. It refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0332, and others.
Guidance Is Nonbinding; Alternatives Allowed
FDA states the guidance represents its current thinking and is not binding on FDA or the public. Manufacturers may use an alternative approach if that approach satisfies the applicable statutes and regulations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10675 — Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
2026-10674 — Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal
The FDA is renewing the Psychopharmacologic Drugs Advisory Committee for two more years, keeping it active until June 4, 2028. This committee helps make sure psychiatric drugs are safe and effective, affecting drug makers, doctors, and patients. No new costs or big changes, just a smooth continuation of expert advice to keep mental health treatments on track.
2026-10703 — Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability
The FDA just released final guidance to help drug companies prove their generic drugs work just like the original ones by using bioequivalence studies. This affects anyone submitting or updating abbreviated new drug applications (ANDAs) and aims to make the approval process clearer and smoother. Companies should review these new rules now to avoid delays and extra costs when getting their generics to market.
2026-10614 — Color Additive Petition from Environmental Defense Fund, et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove three harmful solvents—ethylene dichloride, methylene chloride, and trichloroethylene—from color additive rules. This change affects companies using these solvents in color additives and aims to make products safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any final decisions.
2026-10615 — Food Additive Petition From Environmental Defense Fund, et al.; Request To Amend the Food Additive Regulations To Remove the Solvents Benzene, Ethylene Dichloride, Methylene Chloride, and Trichloroethylene; Reopening of the Comment Period
The FDA is reopening the comment period on a petition from the Environmental Defense Fund and others to remove four harmful solvents—benzene, ethylene dichloride, methylene chloride, and trichloroethylene—from food additive rules. This change affects food makers who use these solvents and aims to make our food safer. Comments are open until June 29, 2026, giving everyone a chance to share new info before any costly changes happen.
2026-10603 — Challenges and Solutions in Lot-Level Food Traceability; Public Meeting and Request for Comments
The FDA is hosting a virtual meeting on June 15, 2026, to talk about how to better track food by its lot number, making food safer and easier to trace. This affects food producers, sellers, and anyone involved in food safety, with a chance to suggest flexible ways to follow the rules. Comments on the ideas are open until July 15, 2026, so get involved and help shape the future of food tracking!
Previous / Next Documents
Previous: 2026-10732 — Information Collection Requirement; Defense Federal Acquisition Regulation Supplement (DFARS), Contract Financing
The Department of Defense is asking to keep collecting info from businesses about contract payments for three more years. This affects about 1,000 companies who respond around 14,000 times a year, spending about 1.2 hours each time. They want your thoughts by July 28, 2026, to make sure the process stays useful and not too time-consuming.
Next: 2026-10735 — Obayashi-Jay Dee Joint Venture; Application for Permanent Variance and Interim Order; Grant of Interim Order; Request for Comments
The Obayashi-Jay Dee Joint Venture asked OSHA for special permission to change some safety rules while working in compressed-air environments on a tunnel project in New Hampshire. OSHA gave them a temporary green light starting May 29, 2026, while they decide if this change can be permanent. Workers and the public can share their thoughts by June 29, 2026, so everyone stays safe and the project keeps moving.